News|Articles|July 1, 2026

5 Allergy Headlines You Missed in June 2026

Fact checked by: Tim Smith

HAE gene editing, peanut patch trials, CSU sequencing, and EAC 2026 highlights in this allergy/immunology roundup for clinicians.

Allergy and immunology specialists have a packed month to catch up on, from late-breaking hereditary angioedema (HAE) data to a first-in-class peanut allergy trial in infants. This roundup covers the latest phase 2 and phase 3 developments, key clinical pearls from the 2026 Eastern Allergy Conference (EAC) in Palm Beach, and a closer look at the everyday realities of living with food allergy.

Related to this article

October 22nd, 2026

FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE

The 150 mg once-daily pellet formulation gives patients aged ≥ 12 years a capsule alternative for HAE prophylaxis.

October 24th, 2026

Kidney Compass: Final 2-Year TELIGAN Data for Telitacicept in IgA Nephropathy

Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.

October 24th, 2026

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.

October 23rd, 2026

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

October 23rd, 2026

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.

October 23rd, 2026

FDA Approves Subcutaneous Risankizumab Induction for Crohn’s Disease

Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.

October 23rd, 2026

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.

October 23rd, 2026

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.